Evidence map›Paper›PMID 27163678›Full record

ArticlePloS one2016

MicroRNA-194 Modulates Glucose Metabolism and Its Skeletal Muscle Expression Is Reduced in Diabetes.

Celine Latouche, Alaina Natoli, Medini Reddy-Luthmoodoo, Sarah E Heywood, James A Armitage, Bronwyn A Kingwell

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 1 synthesis or guideline pooled it, 70 citations in OpenAlex.

  1. A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus.International journal of molecular sciences · 2017
    Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Plasma microRNA Profiling in Type 2 Diabetes Mellitus: A Pilot Study.International journal of molecular sciences · 2023
    Article
  9. Review
  10. Article
  11. BertSRC: transformer-based semantic relation classification.BMC medical informatics and decision making · 2022
    Article
  12. Article
  13. Review
  14. Review
  15. Frontiers in pharmacology · 2022
    Article
  16. Bioengineered · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. The Role of microRNAs in Metabolic Syndrome-Related Oxidative Stress.International journal of molecular sciences · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Celine LatoucheBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Alaina NatoliBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Medini Reddy-LuthmoodooBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Sarah E HeywoodBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
James A ArmitageSchool of Medicine (Optometry), Deakin University, Waurn Ponds, Victoria, Australia.
Bronwyn A KingwellBaker IDI Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Baker Heart and Diabetes Institute · AUDeakin University · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe regulation of microRNAs (miRNAs) at different stages of the progression of type 2 diabetes mellitus (T2DM) and their role in glucose homeostasis was investigated.

methodsMicroarrays were used to assess miRNA expression in skeletal muscle biopsies taken from healthy individuals and patients with pre-diabetes or T2DM, and insulin resistant offspring of rat dams fed a high fat diet during pregnancy.

resultsTwenty-three miRNAs were differentially expressed in patients with T2DM, and 7 in the insulin resistant rat offspring compared to their controls. Among these, only one miRNA was similarly regulated: miR-194 expression was significantly reduced by 25 to 50% in both the rat model and in human with pre-diabetes and established diabetes. Knockdown of miR-194 in L6 skeletal muscle cells induced an increase in basal and insulin-stimulated glucose uptake and glycogen synthesis. This occurred in conjunction with an increased glycolysis, indicated by elevated lactate production. Moreover, oxidative capacity was also increased as we found an enhanced glucose oxidation in presence of the mitochondrial uncoupler FCCP. When miR-194 was down-regulated in vitro, western blot analysis showed an increased phosphorylation of AKT and GSK3β in response to insulin, and an increase in expression of proteins controlling mitochondrial oxidative phosphorylation.

conclusionsType 2 diabetes mellitus is associated with regulation of several miRNAs in skeletal muscle. Interestingly, miR-194 was a unique miRNA that appeared regulated across different stages of the disease progression, from the early stages of insulin resistance to the development of T2DM. We have shown miR-194 is involved in multiple aspects of skeletal muscle glucose metabolism from uptake, through to glycolysis, glycogenesis and glucose oxidation, potentially via mechanisms involving AKT, GSK3 and oxidative phosphorylation. MiR-194 could be down-regulated in patients with early features of diabetes as an adaptive response to facilitate tissue glucose uptake and metabolism in the face of insulin resistance.

Indexed as

AnimalsCell LineDiabetes Mellitus, Type 2Diet, High-FatDisease Models, AnimalFemaleGene Expression RegulationGlucoseGlycogenGlycogen Synthase Kinase 3HumansInsulinInsulin ResistanceMaleMice, Inbred C57BLMicroRNAsGlucoseGlycogenGlycogen Synthase Kinase 3InsulinMicroRNAsMIRN194 microRNA, humanMIRN194 microRNA, ratProto-Oncogene Proteins c-akt

Identifiers

PMID27163678
PMCPMC4862646
OpenAlexW2388693050

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.